← Read
Erectile Dysfunction: What's Really Going On, and What Helps
Body & Health
9 min read
More than half of men over 40 experience it. Fewer talk about it than should.
← Read
Erectile dysfunction - the consistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity - is one of the most common sexual health conditions in men, and one of the least discussed. The combination of prevalence data (the majority of men over 40 experience some degree of it) and the cultural weight attached to erectile function creates a situation where many men suffer a treatable condition in silence, sometimes for years. Understanding what is actually happening physiologically, and what the evidence shows about causes and interventions, is the most direct route out of that silence.
An erection is a haemodynamic event - meaning it depends fundamentally on blood flow. The penis contains two cylindrical chambers of spongy tissue called the corpora cavernosa, running parallel along its length. During sexual arousal, a cascade of neural signals triggers the release of nitric oxide (NO) from the endothelial cells lining the blood vessels of these chambers and from nerve terminals in the erectile tissue itself.
Nitric oxide is the central molecular signal of erection. It activates an enzyme called guanylate cyclase, which produces cyclic GMP (cGMP) - a signalling molecule that causes the smooth muscle cells in the walls of the penile arteries and in the sinusoidal tissue of the corpora cavernosa to relax. When these smooth muscles relax, the arterial vessels dilate, dramatically increasing blood inflow. The sinusoidal spaces fill with blood, compressing the veins that normally drain the penis, creating a veno-occlusive mechanism that traps the blood within the corpora cavernosa and produces the rigidity of erection.
The process reverses when the enzyme phosphodiesterase type 5 (PDE5) breaks down cGMP, restoring muscle tone and allowing venous drainage to resume. This is why PDE5 inhibitors - the class of medication that includes sildenafil - work: they slow the breakdown of cGMP, extending the window during which smooth muscle relaxation and blood retention can occur.
The critical point is that every step of this process depends on the health of the endothelium - the lining of blood vessels. Endothelial dysfunction, caused by inflammation, oxidative stress, or metabolic damage, impairs nitric oxide production and reduces the smooth muscle relaxation response. Most of the lifestyle and medical risk factors for ED work through this mechanism.
Clinically, ED is categorised broadly as psychogenic (originating in psychological or emotional factors), organic (originating in physical pathology), or mixed - which is the most common category, since psychological and physical factors typically interact. Understanding the distinction matters because the appropriate intervention differs substantially between them.
Psychogenic ED is ED that occurs in the absence of identifiable physical pathology and is driven by psychological states - performance anxiety, depression, relationship conflict, past trauma, or spectatoring (the cognitive habit of observing and evaluating one's own sexual performance from outside the experience rather than being present within it). A useful clinical indicator of psychogenic ED is the presence of nocturnal penile tumescence (NPT) - erections during REM sleep - which occurs normally in men with intact vascular function regardless of their waking psychological state. If NPT is normal but daytime erections are impaired, the cause is likely primarily psychogenic.
Performance anxiety deserves particular attention because it operates through a self-reinforcing mechanism. The first episode of erectile failure - which can occur in any man, at any age, for entirely benign situational reasons including tiredness, alcohol, distraction, or stress - creates an anticipatory anxiety about the next sexual encounter. That anxiety activates the sympathetic nervous system, which directly opposes the parasympathetic activity needed for erection. The failed erection confirms the anxiety, intensifying it for the subsequent encounter. The cycle tightens until erectile failure in the relevant context (typically partnered sex) becomes near-consistent, even in men with entirely normal vascular function.
Organic ED has vascular causes in the majority of cases - this is the pathway described above, where endothelial dysfunction reduces nitric oxide availability and impairs the smooth muscle relaxation that drives erection. Hormonal causes (primarily hypogonadism, or low testosterone) account for a smaller proportion. Neurological causes - relevant in men with diabetes-related peripheral neuropathy, spinal cord injury, or post-prostatectomy nerve damage - affect the signalling pathway rather than the vascular mechanism.
The Massachusetts Male Aging Study, published by Feldman and colleagues in 1994 (PubMed 1515981), remains the foundational epidemiological study on ED prevalence. It surveyed a randomly selected population of 1,290 men aged 40 to 70 in the Boston area and found that 52% reported some degree of erectile dysfunction - 17% minimal, 25% moderate, and 10% complete. The prevalence increased substantially with age and with the presence of cardiovascular risk factors including hypertension, diabetes, and heart disease.
More than half of men between 40 and 70 experiencing some degree of ED means it is the statistical norm in this age group, not an aberration. Rates in younger men are also higher than previously thought - estimates of 30% or more of men under 40 report at least occasional ED, with psychogenic and lifestyle factors more prominent than vascular disease in that group. Yafi and colleagues (PubMed 27142056) noted that ED prevalence is rising globally alongside metabolic risk factors - obesity, type 2 diabetes, hypertension - at the same time that effective treatments are more widely available than ever before.
Because most organic ED operates through endothelial dysfunction, the lifestyle factors with the strongest evidence base are the same ones that protect cardiovascular health. Meldrum and colleagues reviewed the intersection of ED and cardiovascular disease in a 2012 paper, noting that penile arteries are small-calibre vessels and often among the first to show endothelial damage - sometimes years before larger cardiac vessels are affected. New-onset ED in a man with cardiovascular risk factors is thus worth taking seriously as an early systemic signal, not only as a sexual health matter.
Aerobic exercise has the strongest evidence. Sustained moderate-to-vigorous aerobic activity (150 minutes per week or more) significantly improves erectile function in men with ED, particularly those with vascular risk factors: it improves endothelial function, increases nitric oxide bioavailability, and reduces inflammation. The benefit is dose-dependent. Smoking cessation also produces measurable erectile improvements, and the benefit accumulates relatively quickly after quitting. Chronic heavy alcohol use impairs both neurological and hormonal aspects of sexual function. Sleep deprivation reduces testosterone (which is predominantly produced nocturnally) and directly impairs erectile function - relevant especially for younger men. Weight loss in overweight men produces meaningful improvements in erectile function through multiple metabolic pathways.
Treatment for ED operates across several categories. Lifestyle modification should be the first intervention for most men with mild to moderate ED - for many, it is sufficient. PDE5 inhibitors (sildenafil, tadalafil, and related medications) are the first-line pharmacological treatment and are effective in roughly 65 to 70% of men with organic ED. They extend the duration of the cGMP signal, facilitating smooth muscle relaxation when sexual stimulation is present. They are not appropriate for men on nitrate medications. Psychotherapy - particularly cognitive behavioural approaches targeting performance anxiety and spectatoring - is the primary intervention for psychogenic ED, and combined psychological plus pharmacological treatment outperforms either alone for mixed cases.
If ED is new, persistent, and affecting quality of life, the right response is to see a doctor. The consultation rules out underlying cardiovascular or hormonal pathology and opens access to the treatments that work. The barrier is almost entirely reluctance to raise the subject - a reluctance that is considerably more intense in anticipation than in the actual conversation. Erectile dysfunction is a physiological response to identifiable causes, most of which can be modified or treated. The majority of men who seek help see measurable improvement.